We are pleased to announce a collaboration with the European Society of Oncology Pharmacy (ESOP). This will focus on one of the unique features of the Oncology Data Network (ODN) – automated algorithm-based regimen mapping.
One of the benefits to hospitals of the ODN’s approach is that clinical teams can keep working with their existing regimen lists and systems. The standardised ODN data model, detailed data science approaches, including automated regimen mapping algorithms enable comparability of treatments across centres.
We have now agreed a collaboration with ESOP to review and evaluate the regimen mapping methodology and algorithms. ESOP is independently forming an expert group of leading oncology pharmacists who will review the techniques and principles of the ODN regimen mapping. The team will then test and compare the output between human experts and the ODN algorithm across multiple European countries and identify any opportunities for further enhancing the methodology.
The ODN’s Clinical and Analytical Steering Committee, chaired by David Kerr, Professor of Cancer Medicine at the University of Oxford commented:
“Oncology centres can have many hundreds and even thousands of regimens and there is a high degree of variation between hospitals which makes it hard to compare treatment approaches. The sophisticated regimen mapping approach we have developed will translate thousands of native regimens into one common “language”. This will transform our ability to identify variations in care and offers an important step towards helping us optimise the care we give our patients. Oncology Pharmacists are on the front line of working with these regimens. We are therefore delighted to be working with ESOP to further enhance and refine our regimen mapping methodology.”
Professor Klaus Meier, President of ESOP added:
“ESOP is looking forward to this collaboration. Our members have a deep insight into regimen variations and see the tremendous value that a systematic regimen mapping approach will bring. We look forward to working with the team at IQVIA to explore the methodologies they have developed and to building on this collaboration to further understand variations in anti-cancer medicine usage and other ways in which information from the ODN can help inform patient care.”